{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:09:39Z","timestamp":1787785779555,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zhejiang Provincial \u201cTrailblazer\u201d R&D Program","award":["2026C01043"],"award-info":[{"award-number":["2026C01043"]}]},{"name":"Zhejiang Province Natural Science Foundation of China","award":["LTGY24H180013"],"award-info":[{"award-number":["LTGY24H180013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07877-4","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T01:54:38Z","timestamp":1775526878000},"page":"5301-5314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Imaging-based stratification of Claudin 18.2-positive gastric adenocarcinoma using 18F-FDG PET\/CT radiomics"],"prefix":"10.1007","volume":"53","author":[{"given":"Chengyang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5164-4821","authenticated-orcid":false,"given":"Heqing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"7877_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"7877_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, Van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"key":"7877_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa073149.","journal-title":"N Engl J Med"},{"key":"7877_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, et al. Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23:169\u201391. https:\/\/doi.org\/10.6004\/jnccn.2025.0022.","journal-title":"J Natl Compr Canc Netw"},{"key":"7877_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"7877_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"key":"7877_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Y-K Kang","year":"2022","unstructured":"Kang Y-K, Chen L-T, Ryu M-H, Oh D-Y, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"key":"7877_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(21)00313-7","volume":"6","author":"R-H Xu","year":"2021","unstructured":"Xu R-H, Zhang Y, Pan H, Feng J, Zhang T, Liu T, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:1015\u201324. https:\/\/doi.org\/10.1016\/S2468-1253(21)00313-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7877_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","volume":"18","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18:473\u201387. https:\/\/doi.org\/10.1038\/s41571-021-00492-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"7877_CR10","doi-asserted-by":"publisher","first-page":"100041","DOI":"10.1016\/j.xinn.2020.100041","volume":"1","author":"Z Lu","year":"2020","unstructured":"Lu Z, Peng Z, Liu C, Wang Z, Wang Y, Jiao X, et al. Current status and future perspective of immunotherapy in gastrointestinal cancers. Innovation. 2020;1:100041. https:\/\/doi.org\/10.1016\/j.xinn.2020.100041.","journal-title":"Innovation"},{"key":"7877_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"The Lancet"},{"key":"7877_CR12","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"7877_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10:38. https:\/\/doi.org\/10.1186\/s40364-022-00385-1.","journal-title":"Biomark Res"},{"key":"7877_CR14","doi-asserted-by":"publisher","first-page":"104000","DOI":"10.1016\/j.esmoop.2024.104000","volume":"9","author":"T-Y Kim","year":"2024","unstructured":"Kim T-Y, Kwak Y, Nam SK, Han D, Oh D-Y, Im S-A, et al. Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. ESMO Open. 2024;9:104000. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104000.","journal-title":"ESMO Open"},{"key":"7877_CR15","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1007\/s00330-024-11186-5","volume":"35","author":"H Yin","year":"2024","unstructured":"Yin H, Luo R, Lv J, Mao W, Shi H. Relationship between [18F]FDG PET\/CT findings and claudin 18.2 expression in metastatic gastric cancer. Eur Radiol. 2024;35:3442\u20139. https:\/\/doi.org\/10.1007\/s00330-024-11186-5.","journal-title":"Eur Radiol"},{"key":"7877_CR16","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1007\/s00259-022-05783-z","volume":"49","author":"L Monaco","year":"2022","unstructured":"Monaco L, De Bernardi E, Bono F, Cortinovis D, Crivellaro C, Elisei F, et al. The \u201cdigital biopsy\u201d in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2022;49:3401\u201311. https:\/\/doi.org\/10.1007\/s00259-022-05783-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7877_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-00956-9","volume":"13","author":"X Zhao","year":"2023","unstructured":"Zhao X, Zhao Y, Zhang J, Zhang Z, Liu L, Zhao X. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET\/CT radiomics. EJNMMI Res. 2023;13:4. https:\/\/doi.org\/10.1186\/s13550-023-00956-9.","journal-title":"EJNMMI Res"},{"key":"7877_CR18","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/j.acra.2024.01.022","volume":"31","author":"L Qin","year":"2024","unstructured":"Qin L, Chen W, Ye Y, Yi H, Pang W, Long B, et al. Prediction of HER2 expression in gastric adenocarcinoma based on preoperative noninvasive multimodal 18F-FDG PET\/CT imaging. Acad Radiol. 2024;31:3200\u201311. https:\/\/doi.org\/10.1016\/j.acra.2024.01.022.","journal-title":"Acad Radiol"},{"key":"7877_CR19","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.21037\/qims-22-148","volume":"13","author":"Q Liu","year":"2023","unstructured":"Liu Q, Li J, Xin B, Sun Y, Wang X, Song S. Preoperative 18F-FDG PET\/CT radiomics analysis for predicting HER2 expression and prognosis in gastric cancer. Quant Imaging Med Surg. 2023;13:1537\u201349. https:\/\/doi.org\/10.21037\/qims-22-148.","journal-title":"Quant Imaging Med Surg"},{"key":"7877_CR20","doi-asserted-by":"publisher","first-page":"155145","DOI":"10.1016\/j.prp.2024.155145","volume":"254","author":"V Angerilli","year":"2024","unstructured":"Angerilli V, Ghelardi F, Nappo F, Grillo F, Parente P, Lonardi S, et al. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion. Pathol Res Pract. 2024;254:155145. https:\/\/doi.org\/10.1016\/j.prp.2024.155145.","journal-title":"Pathol Res Pract"},{"key":"7877_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3322\/caac.21552","volume":"69","author":"WL Bi","year":"2019","unstructured":"Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69:127\u201357. https:\/\/doi.org\/10.3322\/caac.21552.","journal-title":"CA Cancer J Clin"},{"key":"7877_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi C, Chong X, Zhou T, Ma M, Gong J, Zhang M, et al. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study. Chin J Cancer Res. 2024;36:78\u201389. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.01.08.","journal-title":"Chin J Cancer Res"},{"key":"7877_CR23","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1136\/gutjnl-2023-329686","volume":"73","author":"F Zhang","year":"2024","unstructured":"Zhang F, Sahu V, Peng K, Wang Y, Li T, Bala P, et al. Recurrent rhogap gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer. Gut. 2024;73:1280\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2023-329686.","journal-title":"Gut"},{"key":"7877_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X","volume":"92","author":"T Kawamura","year":"2001","unstructured":"Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcinoma: Association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634\u201341.","journal-title":"Cancer"},{"key":"7877_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/BF02984657","volume":"20","author":"A Yamada","year":"2006","unstructured":"Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med. 2006;20:597\u2013604. https:\/\/doi.org\/10.1007\/BF02984657.","journal-title":"Ann Nucl Med"},{"key":"7877_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s13139-010-0058-4","volume":"45","author":"B-H Choi","year":"2011","unstructured":"Choi B-H, Song H-S, An Y-S, Han S-U, Kim J-H, Yoon J-K. Relation between fluorodeoxyglucose uptake and glucose transporter-1 expression in gastric signet ring cell carcinoma. Nucl Med Mol Imaging. 2011;45:30\u20135. https:\/\/doi.org\/10.1007\/s13139-010-0058-4.","journal-title":"Nucl Med Mol Imaging"},{"key":"7877_CR27","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/ncomms5006","volume":"5","author":"HJWL Aerts","year":"2014","unstructured":"Aerts HJWL, Velazquez ER, Leijenaar RTH, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. https:\/\/doi.org\/10.1038\/ncomms5006.","journal-title":"Nat Commun"},{"key":"7877_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.2015151169","volume":"278","author":"RJ Gillies","year":"2016","unstructured":"Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563\u201377. https:\/\/doi.org\/10.1148\/radiol.2015151169.","journal-title":"Radiology"},{"key":"7877_CR29","doi-asserted-by":"publisher","first-page":"e013840","DOI":"10.1136\/jitc-2025-013840","volume":"13","author":"B Qi","year":"2025","unstructured":"Qi B, Jiang Z, Shen H, Li J, Wang Z, Fang M, et al. Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma. J Immunother Cancer. 2025;13:e013840. https:\/\/doi.org\/10.1136\/jitc-2025-013840.","journal-title":"J Immunother Cancer"},{"key":"7877_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, Peerlings J, De Jong EEC, Van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141.","journal-title":"Nat Rev Clin Oncol"},{"key":"7877_CR31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3348\/kjr.2018.0070","volume":"20","author":"JE Park","year":"2019","unstructured":"Park JE, Park SY, Kim HJ, Kim HS. Reproducibility and generalizability in radiomics modeling: possible strategies in radiologic and statistical perspectives. Korean J Radiol. 2019;20:1124. https:\/\/doi.org\/10.3348\/kjr.2018.0070.","journal-title":"Korean J Radiol"},{"key":"7877_CR32","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ijrobp.2018.05.053","volume":"102","author":"A Traverso","year":"2018","unstructured":"Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: a systematic review. Int J Radiat Oncol Biol Phys. 2018;102:1143\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.053.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07877-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07877-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07877-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:47:29Z","timestamp":1782715649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07877-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7877"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07877-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of ZJCH (IRB-2022\u2013375). Given the retrospective nature of the study, the requirement for written informed consent was waived. All procedures followed the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}